You are here

Takeda (JP) acquires stem cell expert TiGenix (Flanders)

Japanese pharma giant Takeda is acquiring Leuven-based biotech company TiGenix for EUR 520 million. Building on TiGenix’s expertise, Takeda will continue to develop stem cell therapies for patients with gastrointestinal disorders. 

Flanders’ research goes US

TiGenix specializes in stem cell therapies. Their latest showpiece is Cx601, a treatment for symptoms associated with Crohn’s disease. To bring their innovation to the clinic, they can now count on their new owner, Takeda.

The two companies are no strangers to each other. Today, Takeda already has a 4.2 percent share in TiGenix, and just last year, the firms signed an agreement to commercialize medicines based on Cx601 in the US. With the new deal, which is expected to take effect in spring 2018, Takeda confirms its belief in Flanders’ thriving biopharma ecosystem. Eduardo Bravo, CEO of TiGenix: “We trust that our stem cell expertise, combined with Takeda’s ambitious mindset and extensive resources, will accelerate the development of stem cell therapies worldwide.” 

More info

TiGenix
Reported by
Reuters
9 January 2018

More investment news about Flanders?

  • Regular updates
  • No spam

Interested in doing business in Flanders?

Let us help you!

  • We can introduce you to other companies, banks and regulators
  • We organize site visits to real estate locations
  • We assist with all legal aspects of setting up a business
  • We're an official government agency
  • Our services are completely free
  • We are a team of international experts

Receive our handbook to growing your business in Flanders

  • It's completely free.
  • Get an overview of all incentives relevant to your company.
  • Tax system explained in-depth.
  • Learn how to set up your business quickly.
  • Discover the benefits of Flanders (in addition to the chocolate).